Cannabics Pharmaceuticals Inc. announced that it has appointed Prof. Zamir Halpern to its Scientific Board of Advisors. Prof. Halpern, Senior Physician at the Gastroenterology institute in the Sourasky Medical Center in Tel-Aviv, Israel, will join the company's scientific board of advisors, moving forward with the clinical validation of the safety and efficacy of the company's novel cannabis formulations for the treatment of colon cancer. Prof. Halpern joins Prof. Amos Toren on the company's scientific advisory board.